Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

NCT00586651 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Polycythemia Vera
Essential Thrombocytosis

Interventions

DRUG: lestaurtinib

Sponsor

Cephalon